Profile data is unavailable for this security.
About the company
Oncolys BioPharma Inc. is a biopharmaceutical company. The Company operates in two business segments. Pharmaceutical business segment is engaged in the research, development, manufacture and marketing of pharmaceuticals. Diagnostic reagents business segment is engaged in the research, development, manufacture and marketing of diagnostic reagents and equipment, as well as the provision of inspection service. The Company's main pipeline includes OBP-301 (Telomelysin), an oncolytic virus; OBP-801, an epigenetic anticancer drug and OBP-601 for the treatment of human immunodeficiency virus (HIV) infection, among others.
- Revenue in JPY (TTM)31.38m
- Net income in JPY-1.91bn
- Incorporated2004
- Employees34.00
- LocationOncolys Biopharma IncToranomon Towers Office4-1-28, ToranomonMINATO-KU 105-0001JapanJPN
- Phone+81 354721578
- Fax+81 354721488
- Websitehttps://www.oncolys.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wakamoto Pharmaceutical Co Ltd | 7.93bn | 190.01m | 8.29bn | 274.00 | 43.47 | 0.6914 | 13.63 | 1.05 | 5.47 | 5.47 | 228.52 | 344.22 | 0.5106 | 2.00 | 3.29 | 28,945,390.00 | 1.22 | -2.28 | 1.39 | -2.64 | 47.52 | 51.00 | 2.40 | -3.97 | 3.48 | -- | 0.0083 | -- | -10.65 | -6.35 | -21.19 | -- | 4.93 | -- |
| K Pharma Inc | 0.00 | -680.95m | 8.31bn | 15.00 | -- | 3.10 | -- | -- | -58.58 | -58.58 | 0.00 | 230.79 | 0.00 | 0.00 | -- | 0.00 | -27.16 | -- | -29.66 | -- | -- | -- | -- | -- | 34.85 | -- | 0.00 | -- | -- | -- | 166.34 | -- | -- | -- |
| Kohjin Bio Co Ltd | -100.00bn | -100.00bn | 8.92bn | 159.00 | -- | 1.69 | -- | -- | -- | -- | -- | 1,032.83 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.73 | -- | 0.2846 | -- | 0.5715 | -- | -53.61 | -- | -- | -- |
| Solasia Pharma KK | 95.00m | -1.21bn | 9.60bn | 24.00 | -- | 4.34 | -- | 101.05 | -6.62 | -6.62 | 0.51 | 10.14 | 0.0408 | 0.5763 | 0.7724 | 3,958,333.00 | -52.22 | -48.57 | -57.64 | -58.83 | 10.53 | 71.01 | -1,278.95 | -300.89 | 7.39 | -- | 0.016 | -- | -43.50 | 14.18 | 56.36 | -- | -- | -- |
| Perseus Proteomics Inc | 108.86m | -966.41m | 9.77bn | 25.00 | -- | 5.32 | -- | 89.78 | -75.66 | -75.66 | 8.50 | 124.71 | 0.0521 | 2.76 | 9.44 | 4,354,200.00 | -46.23 | -41.34 | -48.96 | -43.43 | 89.12 | 91.72 | -887.79 | -891.26 | 15.69 | -101.42 | 0.00 | -- | 6.58 | -18.31 | -40.34 | -- | 60.30 | -- |
| RaQualia Pharma Inc | 2.30bn | -673.00m | 10.08bn | 67.00 | -- | 1.79 | -- | 4.39 | -31.12 | -31.12 | 106.28 | 261.02 | 0.2652 | 3.82 | 2.89 | 34,300,980.00 | -7.77 | 2.13 | -8.56 | 2.26 | 84.78 | 88.49 | -29.28 | 5.32 | 3.55 | -- | 0.3972 | 0.00 | -34.85 | 20.62 | -144.74 | -- | 0.0967 | -- |
| ReproCell Inc | 2.60bn | -196.44m | 10.94bn | 96.00 | -- | 1.25 | -- | 4.21 | -2.21 | -2.21 | 29.29 | 92.79 | 0.2916 | 5.05 | 7.43 | 27,084,280.00 | -2.20 | -7.35 | -2.37 | -8.00 | 51.10 | 39.83 | -7.55 | -27.16 | 8.97 | -- | 0.00 | -- | -17.83 | 17.39 | 89.71 | -- | 13.27 | -- |
| Symbio Pharmaceuticals Ltd | 3.07bn | -4.02bn | 11.11bn | 109.00 | -- | 2.15 | -- | 3.62 | -92.13 | -92.13 | 70.03 | 112.55 | 0.4225 | 2.97 | 4.47 | 28,137,370.00 | -55.36 | -19.18 | -62.58 | -23.62 | 77.57 | 65.84 | -131.05 | -24.32 | 6.51 | -- | 0.00 | -- | -44.15 | 7.82 | -266.45 | -- | 42.39 | -- |
| Ohki Healthcare Holdings Co Ltd | 342.45bn | 1.87bn | 12.00bn | 632.00 | 6.26 | 0.3897 | 5.48 | 0.035 | 136.22 | 136.22 | 24,995.05 | 2,189.15 | 2.45 | 12.90 | 4.52 | 541,849,700.00 | 1.29 | 1.85 | 5.54 | 8.42 | 5.00 | 6.16 | 0.5268 | 0.7178 | 0.8641 | -- | 0.2547 | 13.92 | 9.92 | 5.30 | 1.28 | 1.51 | -5.34 | 5.92 |
| Oncolys Biopharma Inc | 31.38m | -1.91bn | 15.88bn | 34.00 | -- | 7.36 | -- | 505.85 | -94.41 | -94.41 | 1.53 | 86.36 | 0.015 | 0.00 | 0.2917 | 923,058.80 | -91.65 | -45.75 | -104.28 | -51.86 | 0.00 | 60.46 | -6,093.40 | -233.66 | 9.72 | -102.93 | 0.1442 | -- | -93.54 | -17.86 | -68.72 | -- | 28.18 | -- |
| CanBas Co Ltd (Parent) | 0.00 | -1.31bn | 16.25bn | 11.00 | -- | 5.07 | -- | -- | -72.79 | -72.79 | 0.00 | 167.60 | 0.00 | -- | -- | 0.00 | -38.05 | -62.25 | -42.35 | -70.91 | -- | -- | -- | -2,015.62 | -- | -- | -- | -- | -- | -- | 2.77 | -- | -- | -- |
| Stella Pharma Corp | 284.89m | -726.61m | 16.88bn | 44.00 | -- | 5.48 | -- | 59.25 | -22.94 | -22.94 | 8.91 | 90.49 | 0.061 | 0.0433 | 2.59 | 6,474,773.00 | -15.55 | -22.50 | -16.34 | -24.83 | 84.75 | -- | -255.05 | -488.65 | 17.82 | -563.58 | 0.217 | -- | 17.65 | -- | 1.94 | -- | -5.87 | -- |
| TAIKO PHARMACEUTICAL CO LTD | 6.28bn | -2.34bn | 18.38bn | 208.00 | -- | 2.26 | -- | 2.93 | -46.93 | -46.93 | 125.40 | 160.66 | 0.434 | 1.69 | 2.94 | 30,201,920.00 | -16.12 | -- | -19.68 | -- | 55.73 | -- | -37.15 | -- | 2.83 | -- | 0.2166 | -- | 21.43 | -- | 26.23 | -- | -- | -- |
| CellSeed Inc | 199.47m | -957.04m | 19.58bn | 35.00 | -- | 8.93 | -- | 98.16 | -30.72 | -30.72 | 6.40 | 63.29 | 0.0892 | 1.65 | 7.91 | 5,699,172.00 | -42.79 | -49.69 | -46.02 | -54.55 | 55.38 | 63.66 | -479.79 | -428.62 | 16.42 | -5,460.76 | 0.0651 | -- | 50.39 | -28.62 | -11.43 | -- | 80.73 | -- |
| Astena Holdings Co Ltd | 53.39bn | 2.09bn | 20.25bn | 1.40k | 9.39 | 0.6851 | 4.40 | 0.3792 | 52.62 | 52.62 | 1,341.82 | 721.11 | 0.7976 | 3.29 | 2.69 | 38,024,920.00 | 3.12 | 2.49 | 5.76 | 4.44 | 34.11 | 25.33 | 3.91 | 2.32 | 0.879 | 391.65 | 0.349 | 44.92 | 4.73 | -2.85 | 100.61 | -3.85 | 38.54 | 11.38 |
| StemRIM Inc | 0.00 | -2.02bn | 21.96bn | 44.00 | -- | 2.47 | -- | -- | -32.98 | -32.98 | 0.00 | 144.57 | 0.00 | -- | -- | 0.00 | -20.44 | -8.34 | -20.74 | -8.49 | -- | -- | -- | -68.74 | 131.03 | -11,344.72 | 0.00 | -- | -100.00 | -- | -1,301.17 | -- | -4.35 | -- |
Data as of Nov 22 2024. Currency figures normalised to Oncolys Biopharma Inc's reporting currency: Japanese Yen JPY
2.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Evolution Capital Management LLCas of 15 Oct 2024 | 405.00k | 1.63% |
| Simplex Asset Management Co., Ltd.as of 07 Nov 2024 | 109.10k | 0.44% |
Data from 05 Nov 2024 - 14 Nov 2024Source: FactSet Research Systems Inc.
